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In 1999, The American Journal of Pathology published
an article entitled “Vascular Channel Formation by Hu-
man Melanoma Cells in Vivo and in Vitro: Vasculogenic
Mimicry,” by Maniotis and colleagues, which ignited a
spirited debate for several years and earned distinction
as a citation classic. Tumor cell vasculogenic mimicry
(VM) refers to the plasticity of aggressive cancer cells
forming de novo vascular networks, which thereby con-
tribute to perfusion of rapidly growing tumors, trans-
porting fluid from leaky vessels, and/or connecting
with the constitutional endothelial-lined vasculature.
The tumor cells capable of VM share a plastic, transen-
dothelial phenotype, which may be induced by hyp-
oxia. Since VM was introduced as a novel paradigm for
melanoma tumor perfusion, many studies have con-
tributed new findings illuminating the underlying
molecular pathways supporting VM in a variety of
tumors, including carcinomas, sarcomas, glioblasto-
mas, astrocytomas, and melanomas. Facilitating the
functional plasticity of tumor cell VM are key proteins
associated with vascular, stem cell, and hypoxia-re-
lated signaling pathways, each deserving serious con-
sideration as potential therapeutic targets and diag-
nostic indicators of the aggressive, metastatic
phenotype. (Am J Pathol 2012, 181:1115–1125; http://dx.
doi.org/10.1016/j.ajpath.2012.07.013)
A great many studies in pathology have described a high
degree of plasticity associated with aggressive cancer.
Although such reports date back several centuries, formost of that time researchers did not have adequate tools
to elucidate the etiology or the biological implications of
tumor cell plasticity. Molecular tools, in particular, have be-
come available only recently. As a noteworthy example, an
article published by The American Journal of Pathology in
1999 presented a new interpretation for previous findings,
describing cancer cells lining nonendothelial vascular
channels within a tumor mass that contained red blood
cells. The article, entitled “Vascular channel formation by
human melanoma cells in vivo and in vitro: vasculogenic
mimicry,” by Maniotis et al,1 ignited a spirited debate for
several years. A positive commentary about the signifi-
cance of this article, entitled “Tumor plasticity allows vas-
culogenic mimicry, a novel form of angiogenic switch,”
was provided by M.J. Bissell,2 and this was further sup-
ported by a Highlight note in Science3 discussing the
implications of the original article with respect to the
efficacy of angiogenesis inhibitors. A controversial com-
mentary on the topic followed, entitled “Vasculogenic
mimicry: how convincing, how novel, and how signifi-
cant?”4 Briefly, the controversial aspects of this commen-
tary regarding the original VM report focused on several
aspects of the descriptive study and posed the following
questions: i) Are the VM structures blood vessels, and do
they contribute meaningfully to blood flow? ii) Can the
identification of endothelial cells versus tumor cells in
contact with the vascular lumen be established unambig-
uously? and iii) Is there a connection between endothelial
cells and tumor cells in blood vessel walls? Subsequent
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special workshops.
In retrospect, the 1999 article served as the founda-
tional report defining tumor cell VM as the de novo for-
mation of perfusable, matrix-rich, vasculogenic-like net-
works by aggressive tumor cells in three-dimensional
matrices in vitro, which resembles the matrix-rich net-
works observed in aggressive tumors in patients (Figure
1). The hypothesis put forth at the time, based on the
transport of injected fluorescent dye throughout VM net-
works in three-dimensional culture, was that tumor cell
VM serves as a selective advantage to rapidly growing
tumors by providing a perfusion pathway, transporting
fluid from leaky vessels, and/or connecting with tradi-
tional, endothelial-lined vasculature. The genesis of this
new paradigm would not have been possible without the
molecular signature data of aggressive melanoma cells
capable of VM, together with the three-dimensional assay
showing the de novo formation of vascular structures. In
addition, high resolution electron microscopy revealed
Figure 1. Tumor cell vasculogenic mimicry (VM) in vitro and in vivo. A and
in three-dimensional collagen I gels by the end of day 1 (A) and mature into
structures (arrows) can be perfused with a fluorescent dye (the injection s
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The initial morphological, clinical, and molecular char-
acterization of VM was performed using human mela-
noma as a model. These tumor cells were shown to
coexpress endothelial, embryonic/stem cell, and tumor
markers; they were also shown to form channels, net-
works, and tubular structures rich in laminin, collagens IV
and VI, and heparin sulfate proteoglycans and containing
plasma and red blood cells. Collectively, these findings
indicated a perfusion pathway for rapidly growing tu-
mors, and possibly a metastatic escape route. Particu-
larly noteworthy at the time was the rediscovery of an
early report from 1966 (“The growth of the blood supply to
melanoma transplants in the hamster cheek pouch,” by
Warren and Shubik9) suggesting the perfusion of mela-
noma tumors via nonendothelial-lined channels. Another
pertinent published observation, which inspired the term
“tumor cell vasculogenic mimicry,” was the report of
pseudo-vasculogenesis by cytotrophoblasts engaged in
essive human melanoma cells begin to form VM networks (arrows) in vitro
xtensive VM networks (arrows) by day 3 (B). C: By day 14, similar network
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a histological tumor section (H). I: VM networks (arrows) are also seen in
VE-cadherin (green) under immunofluorescence microscopy (I). Original
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observed in human melanoma cells, which led to the
understanding of tumor cell VM as a process that reca-
pitulates early developmental events, including placenta
formation and embryonic vasculogenesis.
Since the initial conceptualization of tumor cell VM in
1999, an impressive body of literature has provided
mechanistic insights into the induction, formation, and
targeting of VM across a variety of cancers, in more than
300 publications (too many to list here). In addition to
melanoma, VM has been studied in carcinomas of the
breast, ovary, lung, prostate, bladder, and kidney; in
sarcomas (Ewing’s, mesothelial, synovial, osteosarcoma,
alveolar rhabdomyosarcoma); and in gliomas, glioblas-
toma, and astrocytoma (reviewed by Paulis et al11). In
several of these studies, including those of melanoma,
Kaplan-Meier survival analyses indicated that patients
with VM in their tumors have a poor clinical outcome,
compared with patients whose tumors do not exhibit VM.
From this accumulating body of evidence, we have a
better perspective of the complexity comprising the tu-
mor vasculature, which can be derived from a variety of
sources, including angiogenic vessels, co-option of pre-
existing vessels, intussusceptive microvascular growth,
mosaic vessels lined by both tumor cells and endothelium,
postnatal vasculogenesis, and VM.12 Moreover, recent
studies have demonstrated the tumor origin of endothelial
Table 1. Gene Expression of Multipotent Aggressive Melanoma
Gene symbol
NODAL embryonic morphogen
NOTCH4 stem cell-related transmem
CDH5† endothelial cell adhesion
TIE1 endothelial receptor tyrosi
EPHA2 epithelial cell kinase
NRP1 VEGF receptor
ESM1 endothelial cell surface pr
S1PR1 (previously EDG1) endothelial G-coupled rec
PDPN elongates endothelial exten
VEGFA growth factor
VEGFC growth factor ligand for FL
SERPINF1 (previously PEDF) antiangiogenic growth fac
THBS1 angiogenesis inhibitor
THBS2 angiogenesis inhibitor
MMP1, MMP2, MMP14 metalloproteinase
LOX ECM remodeling; cell mot
LAMC2† extracellular matrix
FN1 extracellular matrix
TGM2 matrix cross-linking enzym
TFPI coagulation inhibitor
TFPI2 coagulation inhibitor
SPINT2 serine protease inhibitor; c
F3 (alias CD142) coagulation factor/VEGF r
PLAU serine protease
PLAUR GPI-linked urokinase rece
HIF1A hypoxia-inducible transcri
EPAS1 (alias HIF2A) hypoxia-inducible transcri
MLANA (alias MART1) pigment protein (melan-A)
TYRP1 melanin process enzyme
SOX10 melanin pathway transcrip
*Altered gene expression in highly aggressive versus poorly aggress
further validated by Western blot analysis. Differential expression of two
indicating decreased expression.
†CDH5 encodes the VE-cadherin protein (also known as cadherin-5).cells forming the vasculature in glioblastoma,13,14 furthercomplicating the clinical challenges of targeting genetically
unstable and heterogeneous vasculature.
Tumor Cell Plasticity Underlies VM
Tumor cells capable of VM exhibit a remarkable degree
of plasticity, indicative of a multipotent phenotype usually
associated with embryonic stem cells. The molecular sig-
nature of the tumor cell VM phenotype has revealed up-
regulated expression of genes associated with embry-
onic progenitors, endothelial cells, vessel formation,
matrix remodeling, and coagulation inhibitors, as well as
down-regulation of genes predominantly associated with
lineage-specific phenotype markers15 (Table 1). Al-
though the initial microarray studies revealed the differ-
ential molecular profile of highly aggressive versus non-
aggressive human melanoma cells,1,15 later studies
using laser capture microdissection and microgenomics
profiling of melanoma VM networks versus endothelial-
formed angiogenic vasculature confirmed the up-regu-
lated expression of angiogenesis-related genes by the
melanoma cells16 (Figure 2). In addition, this microg-
enomics approach confirmed that plastic tumor cells en-
gaged in VM express key pluripotent stem cell markers.
However, unlike normal embryonic progenitors, these tumor
cells lack critical regulatory checkpoints, a characteristic
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AJP October 2012, Vol. 181, No. 4to unregulated growth and aggressive behavior.17 Recent
studies have shed light on the induction of tumor cell plas-
ticity pertinent to melanoma VM, with the finding that the
hypoxic microenvironment contributes to the phenotype
switch, specifically allowing melanoma cells to contribute to
blood vessel formation.18 Collectively, these accumulating
findings provide supportive evidence for alternative perfu-
sion pathways found in aggressive tumors.
Functional Relevance of VM
The association of VM in patient tumors with a poor clin-
ical outcome implies a functionally relevant advantage
imparted by VM pertinent to the survival of the aggressive
tumor cell phenotype. Experimental landmark studies
have demonstrated a physiological perfusion of blood
between endothelial-lined mouse vasculature and VM
networks in human tumor xenografts, using Doppler im-
Figure 2. Laser capture microdissection (LCM) of melanoma VM versus en
non-network regions (nests) in three-dimensional cultures of aggressive hum
cap. C: Melanoma nests isolated from the VM culture in A on an LCM co
three-dimensional matrix (D) and isolated vascular networks of MV cells on
relative gene expression in the melanoma cells isolated from the nests versus
1, angiogenesis-specific; group 2, ECM and cell adhesion-specific expression fo
3, angiogenesis-specific for aggressive melanoma cells versus MV on Matrigel.aging of circulating microbeads.19,20 Additional findingsfrom these studies elucidated the anticoagulant proper-
ties of tumor cells lining VM networks, facilitating the flow
of blood in aggressive tumors. In this manner, VM can
provide a functional perfusion pathway for rapidly growing
tumors by transporting fluid from leaky vessels and/or con-
necting with endothelial-lined vasculature. A noteworthy ex-
ample of VM functional plasticity and the importance of
hypoxia as a catalyst of this phenotype was demonstrated
with the transplantation of human metastatic melanoma
cells into an ischemic mouse limb, which resulted in forma-
tion of a chimeric vasculature composed of human mela-
noma and mouse endothelial cells.21 After restoring blood
flow to the limb, the melanoma cells formed a large tumor
mass. This finding illustrates the remarkable influence of the
microenvironment on the transendothelial differentiation of
melanoma cells, which reverted to a more tumorigenic phe-
notype as the environmental cues changed.
The functional plasticity associated with VM and the un-
l cell angiogenesis. A: Holes left after excision of tumor cells by LCM from
noma cells. B: Isolated VM networks of melanoma cells on an LCM collection
cap. D and E: Human microvascular endothelial cells (MV) on a Matrigel
collection cap (E). F: Using a gene array, the ratios were determined for
works under the different conditions, and three groups were identified: group
ive melanoma cells in networks versus nests on collagen I matrices; and group
r  400 m. Reproduced with permission from Demou and Hendrix.16dothelia
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the netderlying multipotent tumor cell phenotype are supported by
ASIP Centennial Review 1119
AJP October 2012, Vol. 181, No. 4a complex integration of signaling pathways, which are
typically restricted to events in embryonic development. In
particular, essential VMmodulating genes and proteins can
be categorized into pathways associated with vascular, em-
bryonic/stem cell, and hypoxia-related signaling.22 These
pathways warrant rigorous scientific scrutiny as promising
targets for therapeutic intervention.
Tumor Microenvironment
Studies in developmental biology and tumor progression
have demonstrated that the extracellular microenviron-
ment is not simply a passive structural element in which
cells reside, but can also function as an interactive part-
ner that is changed by, and can subsequently alter, cel-
lular processes and responses. This dynamic reciprocity
between tumor cells and their microenvironment plays an
integral role in VM.
Microarray analyses of nonaggressive compared with
highly aggressive melanoma cells revealed a differential
expression pattern of candidate genes associated with
the extracellular matrix (ECM) and cell-ECM interactions
which could be involved in and facilitate VM (Table 1).
Specifically, it was found that aggressive melanoma cells
express significantly higher levels of the 2 chain (com-
pared with 3 or 3 chains) of the laminin 5 (laminin-332;
Ln5) heterotrimeric basement membrane glycoprotein as
well as matrix metalloproteinases MMP-1, -2, -9, and -14
[MMP-14 is also known as membrane type 1 matrix met-
alloproteinase (MT1-MMP)].7 Furthermore, Ln5 2 chain,
MMP-2, and MMP-14 were found to colocalize with VM
tubular networks formed in a three-dimensional type I
collagen matrix by aggressive (but not nonaggressive)
melanoma cells, and resembled laminin networks in pa-
tient tumor sections of aggressive melanoma (Figure 1),
as well as in human melanoma xenografts in nude mice.
The structural integrity and perfusability of these tubu-
lar networks was demonstrated by injection of a fluores-
cent dye into the lumen of a tubule and by observation of
the subsequent diffusion of the dye throughout the net-
work (Figure 1). The increased expression and specific
localization of these ECM components suggested that
aggressive melanoma cells can modify their ECM to ini-
tiate and promote VM and led to a key observation, that
collagen I three-dimensional matrices preconditioned by
aggressive melanoma cells can induce nonaggressive
melanoma cells and normal melanocytes (which do not
express appreciable levels of Ln5 2 chain) to engage in
VM in response to the Ln5 2 chain and its fragments
deposited by the aggressive cells. Cleavage of Ln5 2
chain by MMP-14 or activated MMP-2 can generate frag-
ments (2 and 2=) that promote vigorous cell scattering,
and it was also demonstrated that melanoma VM could
be inhibited by blocking the expression of Ln5 2 chain
with siRNA, or by treating the cells with a Ln5 function-
blocking antibody or function-blocking antibodies to
MMP-14 and MMP-2 to inhibit the generation of Ln5 2
chain fragments. Furthermore, nonaggressive melanoma
cells could not initiate VM on an aggressive melanoma
cell preconditioned matrix in the presence of a function-blocking antibody to the Ln5 2 chain. Collectively, these
observations demonstrated the integral role that dynamic
reciprocity plays between tumor cells and their microen-
vironment in VM, an understanding that may aid in de-
velopment of targeted therapies directed at the ECM to
alter tumor progression.
Vascular Signaling Pathways
The molecular dissection of the mechanisms involved in
mediating VM began with microarray analyses of highly
aggressive versus nonaggressive human melanoma
cells. These data identified a molecular signature that
revealed the complexity of the signal transduction path-
ways involved in this process.15,23 Two of the first pro-
teins identified to play a role in mediating melanoma VM
were VE-cadherin, a cell-cell adhesion molecule associ-
ated with endothelial cells, and EPHA2, an epithelial cell-
associated kinase involved in ephrin-A1-induced angio-
genesis.24,25 Studies designed to test the role of these
proteins in promoting melanoma VM revealed that down-
regulation of either VE-cadherin or EPHA2 inhibited VM.
Furthermore, it was demonstrated that VE-cadherin could
modulate the location and level of EPHA2 phosphoryla-
tion, providing the first evidence that signal transduction
from the plasma membrane is necessary for melanoma
VM.8 These pivotal experiments prompted additional
studies, which revealed the importance of multiple cyto-
plasmic kinases involved in melanoma VM, including
phosphoinositide 3-kinase (PI3K) and focal adhesion ki-
nase (FAK).26,27 Both PI3K and FAK were found to be
phosphorylated downstream of EPHA2 and VE-cadherin,
leading to increase in the activation of extracellular reg-
ulatory kinases 1 and 2 (ERK1/2), up-regulation of MMP-
14, and increase in MMP-2 activity and the subsequent
cleavage of Ln5 2 chain into the 2= and 2x fragments.
Although the mechanism for increased expression of VE-
cadherin or EPHA2 in human melanoma is not well un-
derstood, in hepatocellular carcinoma VE-cadherin ex-
pression is regulated by the transcription factor Twist 1
and contributes to VM.28
In recent years, many more studies linking various angio-
genesis-promoting factors to VM have been published.
Vascular endothelial growth factor-A (VEGF-A), a well-char-
acterized promoter of endothelial cell proliferation, survival,
and angiogenesis, has been linked to VM in bothmelanoma
and ovarian carcinoma. In melanoma, the autocrine secre-
tion of VEGF-A is required for VM, largely through activation
of VEGF receptor 1 (VEGFR1).29 Although activation of
VEGFR1 leading to downstream activation of PI3K/AKT
pathway is involved in endothelial cell-mediated angio-
genesis, downstream activation of Src and ERK1/2 path-
ways promotes tumor cell invasion and migration.30 In the
case of melanoma, VM appears to be mediated through
the activation of PI3K/PKC downstream of VEGFR1, in
co-operation with integrin-mediated signaling path-
ways.29 Moreover, malignant melanoma initiating cells
expressing the ATP-binding cassette (ABC) member
ABCB5 display a plastic genotype and are able to en-
gage in VM predominately through VEGFR1 mediated
1120 Seftor et al
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ovarian carcinoma cells promoted the up-regulation of
VM-associated genes, including the genes for VE-cad-
herin, EPHA2, MMP-2, and MMP-9.32 These data suggest
that VEGF-A can stimulate characteristics associated
with tumor cell plasticity essential for VM. However, it has
also been demonstrated that EPHA2 can mediate VEGF
expression and VEGF-induced angiogenesis in mam-
mary and pancreatic islet carcinoma cells, suggesting
that, in some cases, EPHA2 may promote tumor cell
plasticity.33
COX-2, an enzyme responsible for catalyzing the con-
version of arachidonic acid into primarily prostaglandin
E2 (PGE2), has also been found to increase the expres-
sion of VEGF through a protein kinase C (PKC) mediated
pathway. PGE2 binds to a family of prostanoid receptors
(prostaglandin E2 receptor subtypes EP1, -2, -3, and -4),
which in turn activate EGF receptor (EGFR) signaling,
and PKC-dependent ERK1/2 activation.34 Signaling
through these pathways promotes tumor cell prolifera-
tion, invasion, angiogenesis, and in some cases VM.34–36
A noninhibitory serpin, pigment epithelium-derived factor
(PEDF, encoded by SERPINF1), has been found to sup-
press angiogenesis through the inhibition of VEGF/
VEGFR-1 signaling, induction of apoptosis, or promotion of
tumor cell differentiation.37 PEDF may also inhibit VM, given
that its expression is typically down-regulated in aggressive
melanoma; moreover, inhibition of PEDF expression in non-
aggressive melanoma cells induces VM.38
Tissue factor (TF) and TF pathway inhibitors TFPI-1
and TFPI-2 are important for the initiation and regulation
of coagulation pathways, and all three have been found
to be up-regulated in aggressive melanoma.20 The ex-
pression and activity of these proteins appear to contribute
Figure 3. Schematic model of signaling pathways implicated in tumor cell
oligonucleotides, small inhibitory RNAs, blocking antibodies, small molecule in
depicted. These molecules are categorized as vascular (red), embryonic/stem c
Molecules shaded with two different colors demonstrate overlap between major
been previously reviewed by Seftor et al.7 Question marks indicate the potential
VM in aggressive cancer cells, for which the underlying signaling pathway or pathways a
by PTGER3). Based on the model of Kirschmann et al.22to the fluid-conducting properties of VM channels and are
necessary for tubular network formation. Taken together,
these data underscore the complexity and diversity of the
signal transduction events that promote and regulate VM in
various cancer types. A composite of known signal trans-
duction events and pathways found to be involved in VM for
various tumor types is shown in Figure 3.
Stem Cell Signaling Pathways in VM
Defined pathways that regulate stem cell behavior and plu-
ripotency also function in tumor cell plasticity and contribute
to VM by aggressive tumor cells. Two pathways critical both
for embryonic stem cell regulation and tumor cell behavior
are the Notch and Nodal signaling pathways,39 and cross-
talk between these pathways regulates tumor cell aggres-
siveness and VM network formation.40
Nodal signaling modulates vertebrate embryogenesis,
functioning in embryonic stem cell pluripotency and in
left-right asymmetry determination41; it is generally ab-
sent from adult tissues, but is reactivated in aggressive
cancers.17,42,43 Nodal is a secreted growth factor and
potent embryonic morphogen belonging to the transform-
ing growth factor- (TGF-) superfamily; it activates sig-
naling via binding to activin-like kinase receptors, type 1
(ALK4, -5, and -7) and type 2 (ACTR-IIB).41,42 Nodal can
signal with or without the coreceptor, cripto-1, to propa-
gate downstream signaling through Smad2/3 and acti-
vate a transcriptional program typically including Nodal
and its antagonist, Lefty. Particularly noteworthy, aggres-
sive cancer cells reactivate Nodal, but not Lefty, whose
promoter is heavily methylated.44 This lack of intrinsic
regulatory control enables Nodal signaling to proceed
y signaling molecules that have been specifically modulated using antisense
, or transient transfections, with demonstrated ability to directly affect VM, are
n), tumor microenvironment (purple), and hypoxia signaling pathways (blue).
aling pathways. Involvement of Gal-3, IL-8, cAMP, and EPAC 1/Rap1 in VM has
ent of a protein and/or downstream effector protein or proteins in modulatingVM. Onl
hibitors
ell (gree
VM sign
involvemre not yet clearly defined. EP3, prostaglandin E receptor EP3 subtype (encoded
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and plasticity.17,42,43 Nodal mRNA is expressed in the
melanoma cells contributing to VM structures,45 and
Nodal protein is detected in a subpopulation of cultured
melanoma and breast cancer cells.40,46 Targeting ALK
receptor activation with chemical inhibitors or Nodal with
neutralizing antibodies reduced the ability of aggressive
melanoma cancer cells to engage in VM on three-dimen-
sional matrices.42,47
The highly conserved Notch signaling pathway func-
tions in stem cell differentiation and self-renewal in vari-
ous niches of embryonic and adult tissues.48 Single
transmembrane Notch receptors (Notch 1 to Notch 4) are
typically activated by a membrane-tethered ligand
(DLL1/2/4 or JAG1/2) on an adjacent cell, and binding
triggers proteolytic cleavage events that release the
Notch intracellular domain into the cytoplasm.39,48 The
Notch intracellular domain associates with a transcription
factor complex to activate transcription of downstream
target genes. During embryonic body plan establish-
ment, Notch signaling regulates Nodal gene expression
to direct left-right axis determination,49,50 and this cross-
talk between Notch and Nodal is recapitulated in mela-
noma, in which Notch 4 signaling controls Nodal gene
expression to regulate tumor cell aggressiveness and
plasticity, including VM.40 Notch 4 expression is enriched
in melanoma VM networks,16 and targeting Notch 4 ac-
tivity with function-blocking antibodies diminished VM for-
mation in vitro, concomitant with a reduction in VE-cad-
herin expression.40 Importantly, VM network formation
and VE-cadherin expression could be rescued by adding
recombinant Nodal protein to the melanoma cell culture.
Because VM may represent an alternative mechanism for
tumor perfusion, targeting the Notch 4-Nodal signaling
axis has potential for treatment strategies (Figure 3).
Table 2. Angiogenesis Inhibitors and Effect on VM
Therapeutic agents*
Molecular t
functi
Monoclonal antibodies
bevacizumab (Avastin) VEGF
cetuximab (Erbitux) EGFR
panitumumab (Vectibix) EGFR
Small molecule tyrosine kinase inhibitors
sunitinib (Sutent) VEGFRs, PDG
sorafenib (Nexavar) VEGFRs, PDG
erlotinib (Tarceva) EGFR
imatinib (Gleevec, Glivec) TK inhibition; B
gefitinib (Iressa) EGFR
pazopanib (Votrient, GW786034) VEGFRs, PDG
lapatinib (Tykerb) EGFR, HER2
Other antiangiogenic agents and
angiogenesis inhibitors
thalidomide (Thalomid) TNF; ROS pr
TNP-470 (AGM-1470) TK inhibition
endostatin (rhEndostatin, Endostar) integrin signali
sirolimus† (Rapamune) mTOR, VEGF
curcumin EPHA2, PI3K,
isoxanthohumol TGF- signalin
vadimezan (ASA404, AS1404, DMXAA) MAPK, VE-cad
resveratrol VEGFR1, VEG
*Generic and INN names are given first, with applicable trade name,
†Sirolimus is also known as rapamycin.
ND, not determined; VM, vasculogenic mimicry.Hypoxia-Related Signaling Pathways
Hypoxia, either persistent or transient, is a hallmark of
most solid tumors and can regulate pathways in cellular
differentiation, induction/maintenance of stem cell-like
characteristics, tumor progression, radio- and chemore-
sistance, angiogenesis, and VM, all of which are markers
of poor prognosis in patients. The hypoxia-inducible fac-
tor (HIF) complex (comprised of HIF-1 and one HIF-
subunit: HIF-1, HIF-2, or HIF-3) is a key regulator of
oxygen homeostasis in both physiological and patholog-
ical environments. Under low oxygen availability, HIF-1
undergoes protein stabilization and translocates into the
nucleus, where it binds to gene regulatory regions con-
taining hypoxia response elements and activates tran-
scription of hypoxia-target genes (reviewed by De Bock
et al51 and by Benizri et al52). In particular, hypoxia and
subsequent HIF overexpression in tumor cells induces
the expression of gene products that are involved in
angiogenesis (eg, VEGF), which is essential for cell via-
bility, tumor growth, and metastasis. Recently, hypoxia
has also been shown to induce VM in hepatocellular
carcinoma, Ewing’s sarcoma, and melanoma. In addition,
hypoxia can induce a dedifferentiated phenotype in
breast carcinoma.22
Pertinent to VM, hypoxia can directly modulate
VEGF-A, VEGFR1, EPHA2, Twist, Nodal, osteopontin,
and COX-2 gene expression (via HIF/hypoxia response
element binding) or indirectly modulate VE-cadherin, TF,
and PEDF expression (via activation of an intermediary
protein that regulates gene transcription or posttranscrip-
tional protein processing).53 In addition, hypoxia can
modulate the expression of Notch-responsive genes via
HIF-1 stabilization of the Notch intracellular domain pro-
tein and subsequent activation of genes with Notch-re-
r
Effect on VM References
no effect Wang et al14
ND
ND
ET ND
af-1 ND
ND
L inhibition Paulis et al60
ND
-Kit ND
ND
inhibition Zhang et al61
no effect van der Schaft et al62
no effect van der Schaft et al62; Liu et al63
inhibition Su et al64
inhibition Chen et al65
inhibition Serwe et al66
inhibition Zhao et al67
inhibition Vartanian et al29
ame, or abbreviation in parenthesis.arget o
on
FR-, R
FR-, R
CR-AB
FR-, c
oducer
ng
MMPs
g
herin
FR2
code n
1122 Seftor et al
AJP October 2012, Vol. 181, No. 4sponsive promoters, including Nodal. This noncanonical
crosstalk between HIF-1 and Notch signaling pathways
is thought to promote an undifferentiated cell state, fur-
ther illuminating the possible etiology of tumor cell plas-
ticity underlying VM. Another mechanism by which hyp-
oxia can promote VM is through the generation of
mitochondrial reactive oxygen species. Redox-depen-
dent stabilization of HIF-1 and induction of VM have
been demonstrated in melanoma.29,54 These studies
demonstrating hypoxia-induced VM and VM-associated
genes highlight the critical role for hypoxia in tumor pro-
gression (Figure 3). Indeed, treatment with some antiangio-
genic agents, which inhibit tumor perfusion and increase
intratumoral hypoxia, has demonstrated increased metas-
tasis and VM.51,55,56
Translational Promise
VM has been reported across a broad range of solid
tumors, and specifically in association with an aggressive
and metastatic phenotype (reviewed by Paulis et al11).
Establishing histopathology protocols for validating VM,
however, has been hampered by the lack of universal
markers. The earliest VM studies stained patient tissues
with PAS (omitting hematoxylin counterstaining, to re-
duce visual noise) to outline the ECM networks, together
with dual immunohistochemistry staining for a tumor-spe-
cific marker (such as HMB-45 for melanoma) plus a vas-
cular marker (such as VE-cadherin or TIE1), with final
validation by transmission electron microscopic evidence
of tumor cell-lined channels containing red blood cells.1
This approach was cumbersome to deploy and difficult to
replicate consistently across laboratories. Better recog-
nition of tumor cell VM has evolved, based on the results
of molecular studies indicating a plastic, stem cell-like
phenotype underlying VM. Most noteworthy is the obser-
vation that tumor cells engaged in VM can express
ABCB5 (a chemoresistance gene), which coincides with
a malignant melanoma-initiating subpopulation,31 a find-
ing that underscores the importance of identifying VM
targets to effectively treat aggressive tumors. Collec-
tively, these studies can guide pathologists to identify VM
in patient tissues as an indicator of an aggressive tumor
cell phenotype and as a predictor of chemoresponsive-
ness and, ultimately, disease outcome. Nonetheless, fur-
ther validation of specific VM markers across various
cancers is necessary before VM analysis can be ac-
cepted as an integral part of histopathology reports.
Although the use of antiangiogenic compounds to tar-
get the blood supply of a tumor seems logical, the suc-
cess of these compounds in the clinic has thus far been
very limited. Bevacizumab, sorafenib, and sunitinib have
all been used clinically to treat various cancers, with
limited efficacy. Clinical use of these drugs has been
shown to limit the growth of the primary tumor, but long-
lasting effects are rare and typically lead to only moder-
ate benefits for overall survival.57 In breast cancer, the
preclinical and clinical results are likely due to the devel-
opment of a hypoxic microenvironment within the tumor
leading to the proliferation of cancer stem cells, a celltype with the greatest degree of plasticity and ability to
metastasize.58 Moreover, there is evidence suggesting
that a hypoxic microenvironment within a tumor may pro-
mote the development of tumor-derived endothelial cells
in glioblastoma.59 Although these tumor-derived endo-
thelial cells still express tumor-specific markers, they are
otherwise indistinguishable from conventional endothelial
cells. Interestingly, although the differentiation of glio-
blastoma cells into endothelial cells requires a hypoxic
microenvironment, the mechanism was reported to be
independent of VEGF-mediated or FGF-mediated signal-
ing.59 Taken together, these data underscore the need
for the continued development of treatment strategies
that target the plastic phenotype and microenvironment
of aggressive tumor cells.
Considering the diverse nature of vascular perfusion
pathways in tumors, it may be prudent to test the efficacy
of currently available angiogenesis inhibitors on tumor
cell VM, in addition to endothelial cell-driven angiogene-
sis (Table 2). For example, curcumin, imatinib, and tha-
lidomide have all been shown to inhibit melanoma VM,
concomitant with decreases in EPHA2, VE-cadherin,
PI3K, VEGF, HIF-1, MMP-2, and MMP-9 expression
and/or activity, suggesting that these compounds can
affect several different aspects of the signaling mecha-
nisms mediating VM.61,63,65 ASA404 (DMZAA), a small
molecule vascular disrupting agent, was found to inhibit
melanoma VM through a p38 MAPK-dependent mecha-
nism.67 Isoxanthohumol, an inhibitor of TGF- inducible
genes related to angiogenesis and metastasis, was able
to block VM in breast cancer cells.66 Rapamycin (siroli-
mus), an inhibitor of mTOR and HIF-1, was able to
Figure 4. Endostatin disrupts angiogenesis but not VM. A: Bright-field mi-
crograph of human microvascular endothelial cells-1 (HMEC-1) cultured on
a three-dimensional collagen I gel for 3 days in the presence of 10 g/mL of
recombinant human (rh) endostatin. B: Bright-field micrograph of PAS-
stained aggressive human melanoma cells cultured on a three-dimensional
collagen I gel for 6 days in the presence of 10 g/mL of recombinant human
endostatin. C: Western blot analysis shows the relative differences among
endostatin receptor 5-integrin subunit protein expression levels in whole-
cell lysates from aggressive human melanoma cells (C8161), human umbilical
vein endothelial cells (HUVEC), and HMEC-1 cells. -Actin was used as a
control for equal loading, and protein amounts were determined relative to
-actin. D: Semiquantitative RT-PCR shows the relative expression levels of
integrin 5 subunit mRNA in C8161, HUVEC, and HMEC-1 cells. GAPDH was
used as a control for both loading and relative levels of expression. Original
5magnification: 100. Reproduced with permission from Hendrix et al
(A and B) and from van der Schaft et al62 (C and D).
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tion of CD31 and factor VIII.64 By contrast, endostatin is
ineffective in inhibiting melanoma VM, largely because
these tumor cells lack the appropriate target receptors for
an effective response62 (Figure 4). Interestingly, Endo-
star, a novel recombinant form of human endostatin, has
shown limited ability inhibiting VM in glioblastoma in vitro
(although the mechanism for this biological effect re-
mains unknown).63
It seems plausible that the most efficient way to target
tumor cell plasticity is to inhibit multiple signaling path-
ways simultaneously. For example, for the non-small cell
lung carcinoma cell line MV-522, treatment with anti-
VEGF antibodies in conjunction with anti-delta-like ligand
4 (Dll4) antibodies resulted in the greatest inhibition of
tumor growth in mice over a period of 35 days.68 Similar
results were demonstrated in glioblastoma, in which ec-
topic expression of Dll4 could impart resistance to bev-
acizumab in vivo; however, this resistance could be re-
versed when tumor xenografts were concomitantly
treated with dibenzazepine.69 Moreover, bevacizumab
had no effect on the ability of a subpopulation of CD133
glioblastoma cells to differentiate into endothelial progen-
itor cells; however, this transition could be blocked
through inhibition of -secretase or Notch 1 silencing.14
Considering future development of new treatment
strategies, it is evident that suppression of master plas-
ticity pathways associated with promoting VM, increased
tumorigenicity, and stemness of tumor cell populations
has resulted in substantial inhibition of tumor progres-
sion. Moreover, VM is considered a reliable predictor of
clinical outcome for various cancer types.22 Identification
of VM within patient samples may serve in a new classi-
fication scheme based on tumor cell plasticity, thus iden-
tifying cases requiring an aggressive treatment strategy
consisting of combinatorial targets (Figure 3).
Concluding Remarks
The foundational studies underlying tumor cell VM and
the transendothelial differentiation of tumor cells illumi-
nate the importance of achieving a better understanding
of the molecular pathways governing tumor cell plasticity.
Given the findings that aggressive tumor cells express
endothelial markers, it is critical that the appropriate re-
agents are used to unequivocally distinguish tumor cells
from endothelial cells. Although a great deal of contro-
versy erupted over the initial VM reports, these criticisms
compelled more rigorous scientific scrutiny of the new
VM paradigm. Ultimately, the emerging discoveries sur-
rounding VM are leading to more accurate histopathol-
ogy interpretations and novel cancer therapies directed
toward combinatorial targets.
Acknowledgments
We thank Drs. Robert Folberg, Andrew Maniotis, Anil
Sood, Daisy van der Schaft, Arjan Griffioen, Zoe Demou,
Paul Meltzer, Jeffrey Trent, Vito Quaranta, Wolfram Ruf,
and Lynne-Marie Postovit for their critical contributions.References
1. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J,
Trent JM, Meltzer PS, Hendrix MJC: Vascular channel formation by
human melanoma cells in vivo and in vitro: vasculogenic mimicry.
Am J Pathol 1999, 155:739–752
2. Bissell MJ: Tumor plasticity allows vasculogenic mimicry, a novel form
of angiogenic switch. A rose by any other name? Am J Pathol 1999,
155:675–679
3. Barinaga M: New type of blood vessel found in tumors. Science 1999,
285:1475
4. McDonald DM, Munn L, Jain RK: Vasculogenic mimicry: how con-
vincing, how novel, and how significant? Am J Pathol 2000, 156:383–
388
5. Hendrix MJC, Seftor EA, Hess AR, Seftor REB: Vasculogenic mimicry
and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer
2003, 3:411–421
6. Sood AK, Seftor EA, Fletcher MS, Gardner LMG, Heidger PM, Butler
RE, Seftor REB, Hendrix MJC: Molecular determinants of ovarian
cancer plasticity. Am J Pathol 2001, 158:1279–1288
7. Seftor REB, Seftor EA, Koshikawa N, Meltzer PS, Gardner LMG,
Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJC: Cooper-
ative interactions of laminin 5 gamma2 chain, matrix metalloprotei-
nase-2, and membrane type-1-matrix/metalloproteinase are required
for mimicry of embryonic vasculogenesis by aggressive melanoma.
Cancer Res 2001, 61:6322–6327
8. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor REB, Hendrix MJC:
VE-cadherin regulates EphA2 in aggressive melanoma cells through
a novel signaling pathway: implications for vasculogenic mimicry.
Cancer Biol Ther 2006, 5:228–233
9. Warren BA, Shubik P: The growth of the blood supply to melanoma
transplants in the hamster cheek pouch. Lab Invest 1966, 15:464–
478
10. Damsky CH, Fisher SJ: Trophoblast pseudo-vasculogenesis: faking it
with endothelial adhesion receptors. Curr Opin Cell Biol 1998, 10:
660–666
11. Paulis YWJ, Soetekouw PM, Verheul HMW, Tjan-Heijnen VCG, Grif-
fioen AW: Signalling pathways in vasculogenic mimicry. Biochim
Biophys Acta 2010, 1806:18–28
12. Döme B, Hendrix MJC, Paku S, Tovari J, Timar J: Alternative vascu-
larization mechanisms in cancer: pathology and therapeutic implica-
tions. Am J Pathol 2007, 170:1–15
13. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T,
Maira G, Parati EA, Stassi G, Larocca LM, De Maria R: Tumour
vascularization via endothelial differentiation of glioblastoma stem-
like cells [Erratum appeared in Nature 2011, 477:238, and in Nature
2011, 469:432]. Nature 2010, 468:824–828
14. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Gever A,
Fligelman B, Leversha M, Brennan C, Tabar V: Glioblastoma stem-like
cells give rise to tumour endothelium. Nature 2010, 468:829–833
15. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor EA, Hendrix MJC,
Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty
E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P,
Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M,
Alberts D, Sondak V: Molecular classification of cutaneous malignant
melanoma by gene expression: shifting from a continuous spectrum
to distinct biologic entries. Nature 2000, 406:536–540
16. Demou Z, Hendrix MJC: Microgenomics profile of the endogenous
angiogenic phenotype in subpopulations of aggressive melanoma.
J Cell Biochem 2008, 105:562–573
17. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A,
Wheaton WW, Abbott DE, Seftor REB, Hendrix MJC: Human embry-
onic stem cell microenvironment suppresses the tumorigenic pheno-
type of aggressive cancer cells. Proc Nat Acad Sci USA 2008,
105:4329–4334
18. Mihic-Probst D, Ikenberg K, Tinguely M, Schrami P, Behnke S, Seifert
B, Civenni G, Sommer L, Moch H, Dummer R: Tumor cell plasticity
and angiogenesis in human melanoma. PLoS One 2012, 7:e33571
19. Hendrix MJC, Seftor EA, Meltzer PS, Hess AR, Gruman LM, Nickoloff
BJ, Miele L, Sheriff DD, Schatteman GC, Bourdon MA, Seftor REB:
The stem cell plasticity of aggressive melanoma tumor cells. Stem
Cells Handbook. Edited by S Sell. Totowa NJ, Humana Press, 2000,
pp 297–306
1124 Seftor et al
AJP October 2012, Vol. 181, No. 420. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan
NV, Seftor REB, Miyagi Y, Hendrix MJC: Differential role of tissue
factor pathway inhibitors 1 and 2 (TFPI-1 and 2) in melanoma vascu-
logenic mimicry. Cancer Res 2003, 63:5381–5389
21. Hendrix MJC, Seftor REB, Seftor EA, Gruman LM, Lee LM, Nickoloff
BJ, Miele L, Sheriff DD, Schatteman GC: Transendothelial function of
human metastatic melanoma cells: role of the microenvironment in
cell-fate determination. Cancer Res 2002, 62:665–668
22. Kirschmann DA, Seftor EA, Hardy KM, Seftor REB, Hendrix MJC:
Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic
and therapeutic implications. Clin Cancer Res 2012, 18:2726–2732
23. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR,
Kirschmann DA, Seftor REB, Hendrix MJC: Expression of multiple
molecular phenotypes by aggressive melanoma tumor cells: role in
vasculogenic mimicry. Crit Rev Oncol Hematol 2002, 44:17–27
24. Hendrix MJC, Seftor EA, Meltzer PS, Gardner LM, Hess AR,
Kirschmann DA, Schatteman GC, Seftor REB: Expression and func-
tional significance of VE-cadherin in aggressive human melanoma
cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001,
98:8018–8023
25. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB,
Seftor REB, Kinch MS, Hendrix MJC: Molecular regulation of tumor
cell vasculogenic mimicry by tyrosine phosphorylation: role of epithe-
lial cell kinase (Eck/EphA2). Cancer Res 2001, 61:3250–3255
26. Hess AR, Hendrix MJC: Focal adhesion kinase signaling and the
aggressive melanoma phenotype. Cell Cycle 2006, 5:478–480
27. Hess AR, Seftor EA, Seftor REB, Hendrix MJC: Phosphoinositide
3-kinase regulates membrane type 1-matrix metalloproteinase (MMP)
and MMP-2 activity during melanoma cell vasculogenic mimicry.
Cancer Res 2003, 63:4757–4762
28. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J,
Liu YX, Sun BC: Expression and functional significance of Twist1 in
hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatol-
ogy 2010, 51:545–556
29. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A,
Lichinitser M: VEGFR1 and PKCalpha signaling control melanoma
vasculogenic mimicry in a VEGFR2 kinase-independent manner. Mel-
anoma Res 2011, 21:91–98
30. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L: Signal trans-
duction by vascular endothelial growth factor receptors. Biochem J
2011, 437:169–183
31. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR,
Osherov V, Widlund HR, Gasser M, Waaga-Gasser AM, Kupper TS,
Murphy GF, Frank MH: VEGFR-1 expressed by malignant melanoma-
initiating cells is required for tumor growth. Cancer Res 2011, 71:
1474–1485
32. Wang JY, Sun T, Zhao XL, Zhang SW, Zhang DF, Gu Q, Wang XH,
Zhao N, Qie S, Sun BC: Functional significance of VEGF-A in human
ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther
2008, 7:758–766
33. Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP,
Bussell KN, Reith A, Jackson D, Chen J: Inhibition of VEGF-depen-
dent multistage carcinogenesis by soluble EphA receptors. Neopla-
sia 2003, 5:445–456
34. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH: Cyclooxygenase-2 in
tumorigenesis of gastrointestinal cancers: an update on the molecu-
lar mechanisms. Cancer Lett 2010, 295:7–16
35. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj
BA, Mukherjee P: A novel role for cyclooxygenase-2 in regulating
vascular channel formation by human breast cancer cells. Breast
Cancer Res 2006, 8:R69
36. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cris-
tofanilli M: Differential regulation of the aggressive phenotype of
inflammatory breast cancer cells by prostanoid receptors EP3 and
EP4. Cancer 2010, 116(11 Suppl):2806–2814
37. Hoshina D, Abe R, Yamagishi SI, Shimizu H: The role of PEDF in tumor
growth and metastasis. Curr Mol Med 2010, 10:292–295
38. Orgaz JL, Ladhani O, Hoek KS, Fernández-Barral A, Mihic D, Aguil-
era O, Seftor EA, Bernad A, Rodríguez-Peralto JL, Hendrix MJ, Vol-
pert OV, Jiménez B: Loss of pigment epithelium-derived factor en-
ables migration, invasion and metastatic spread of human melanoma.
Oncogene 2009, 28:4147–416139. Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschmann DA, Seftor REB,
Postovit LM, Hendrix MJC: Development and cancer: at the cross-roads of Nodal and Notch signaling [Erratum appeared in Cancer
Res 2009, 69:8526–7]. Cancer Res 2009, 69:7131–7134
40. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM,
Strizzi L, Hendrix MJC: Regulation of the embryonic morphogen
Nodal by Notch4 facilitates manifestation of the aggressive mela-
noma phenotype. Cancer Res 2010, 70:10340–10350
41. Schier AF: Nodal signaling in vertebrate development. Annu Rev Cell
Dev Biol 2003, 19:589–621
42. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR,
Wheaton WW, Nickoloff BJ, Topczewski J, Hendrix MJC: Embryonic
and tumorigenic pathways converge via Nodal signaling: role in
melanoma aggressiveness. Nat Med 2006, 12:925–932
43. Strizzi L, Hardy KM, Kirschmann DA, Ahrlund-Richter L, Hendrix MJC:
Nodal expression and detection in cancer: experience and chal-
lenges. Cancer Res 2012, 72:1915–1920
44. Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K,
Bonaldo Mde F, Soares MB, Hendrix MJC: Epigenetically reprogram-
ming metastatic tumor cells with an embryonic microenvironment.
Epigenomics 2009, 1:387–398
45. McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF: The
embryonic morphogen, Nodal, is associated with channel-like struc-
tures in human malignant melanoma xenografts J Cutan Pathol 2010,
37 Suppl 1:19–25
46. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B,
Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix
MJC: Potential for the embryonic morphogen Nodal as a prognostic and
predictive biomarker in breast cancer. Breast Cancer Res 2012, 14:R75
47. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C,
Seftor REB, Seftor EA, Hendrix MJC: Nodal as a biomarker for mela-
noma progression and a new therapeutic target for clinical interven-
tion. Expert Rev Dermatol 2009, 4:67–78
48. Liu J, Sato C, Cerletti M, Wagers A: Notch signaling in the regulation
of stem cell self-renewal and differentiation. Curr Top Dev Biol 2010,
92:367–409
49. Krebs LT, Iwai N, Nonaka S, Welsh IC, Lan Y, Jiang R, Saijoh Y,
O’Brien TP, Hamada H, Gridley T: Notch signaling regulates left-right
asymmetry determination by inducing Nodal expression. Genes Dev
2003, 17:1207–1212
50. Raya A, Kawakami Y, Rodriguez-Esteban C, Buscher D, Koth CM,
Itoh T, Morita M, Raya RM, Dubova I, Bessa JG, de la Pompa JL,
Izpisua Belmonte JC: Notch activity induces Nodal expression and
mediates the establishment of left-right asymmetry in vertebrate em-
bryos. Genes Dev 2003, 17:1213–1218
51. De Bock K, Mazzone M, Carmeliet P: Antiantiogenic therapy, hypoxia,
and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011,
8:393–404
52. Benizri E, Ginouvès A, Berra E: The magic of the hypoxia-signaling
cascade. Cell Mol Life Sci 2008, 65:1133–1149
53. Fernández-Barral A, Orgaz JL, Gomez V, del Peso L, Calzada MJ,
Jiménez B: Hypoxia negatively regulates antimetastatic PEDF in mel-
anoma cells by a hypoxia inducible factor-independent, autophagy
dependent mechanisms. PLoS One 2012, 7:e32989
54. Comito G, Calvani M, Giannoni E, Bianchini R, Calorini L, Torre E,
Migliore C, Giordano S, Chiarugi P: HIF-1 stailization by mitochondrial
ROS promotes Met-dependent invasive growth and vasculogenic mim-
icry in melanoma cells. Free Radic Biol Med 2011, 51:893–904
55. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL: Short-term anti-vascular
endothelial growth factor treatment elicits vasculogenic mimicry for-
mation of tumors to accelerate metastasis. J Exp Clin Cancer Res
2012, 31:16
56. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG,
Kerbel RS: Accelerated metastasis after short-term treatment with a
potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232–239
57. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic ther-
apy. Nat Rev Cancer 2008, 8:592–603
58. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H,
Heath AN, Clouthier SG, Wicha MS: Antiangiogenic agents increase
breast cancer stem cells via the generation of tumor hypoxia. Proc
Natl Acad Sci USA 2012, 109:2784–2789
59. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue
H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM: Transdif-
ferentiation of glioblastoma cells into vascular endothelial cells. Proc
Natl Acad Sci USA 2011, 108:4274–4280
ASIP Centennial Review 1125
AJP October 2012, Vol. 181, No. 460. Paulis YWJ, Dinnes D, Soetekouw PMMB, Nelson PJ, Burdach S,
Loewe RP, Tjan-Heijnen VCG, Luettichau IV, Griffioen AW: Imatinib
reduces the vasculogenic potential of plastic tumor cells. Current
Angiogenesis 2012, 1:64–71
61. Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y, Sun B: Thalidomide influences
growth and vasculogenic mimicry channel formation in melanoma. J
Exp Clin Cancer Res 2008, 27:60
62. van der Schaft DW, Seftor REB, Seftor EA, Hess AR, Gruman LM,
Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJC: Effects of
angiogenesis inhibitors on vascular network formation by human
endothelial and melanoma cells. J Natl Cancer Inst 2004, 96:
1473–1477
63. Liu Z, Li Y, Zhao W, Ma Y, Yang X: Demonstration of vasculogenic
mimicry in astrocytomas and effects of Endostar on U251 cells. Pathol
Res Pract 2011, 207:645–651
64. Su M, Feng YJ, Yao LQ, Cheng MJ, Xu CJ, Huang Y, Zhao YQ, Jiang
H: Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mim-
icry in vivo. Int J Gynecol Cancer 2008, 18:476–48665. Chen LX, He YJ, Zhao SZ, Wu JG, Wang JT, Zhu LM, Lin TT, Sun BC, Li
XR: Inhibition of tumor growth and vasculogenic mimicry by curcuminthrough down-regulation of the EphA2/PI3K/MMP pathway in a murine
choroidal melanoma model. Cancer Biol Ther 2011, 11:229–235
66. Serwe A, Rudolph K, Anke T, Erkel G: Inhibition of TGF-beta signal-
ing, vasculogenic mimicry and proinflammatory gene expression by
isoxanthohumol. Invest New Drugs 2012, 30:898–915
67. Zhao L, Marshall ES, Kelland LR, Baguley BC: Evidence for the
involvement of p38 MAP kinase in the action of the vascular disrupt-
ing agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest
New Drugs 2007, 25:271–276
68. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y,
Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan
C, Hongo JA, de Sauvage F, Plowman G, Yan M: Inhibition of Dll4
signalling inhibits tumour growth by deregulating angiogenesis. Na-
ture 2006, 444:1083–1087
69. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E,
Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ,
Montgomery CP, Poulsom R, Harris AL: DLL4-Notch signaling medi-
ates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011,
71:6073–6083
